Monitoring Quality Control During CAR
T-Cell Manufacturing Process
Cutting-edge chimeric antigen receptor (CAR) T-cell therapies are revolutionizing cancer treatment. As new CAR T-cell products are brought to preclinical trials, scientists need quality control practices to maximize the therapies' potential to help patients while minimizing the risk for harm.
In this article, discover how Droplet Digital™ PCR provides the sensitivity, precision, and versatility needed to improve quality control for the CAR T-cell manufacturing process, including:
- How the right technology helps achieve the right dose
- How CAR T-cell persistence can be monitored
- How to detect replication-competent viruses and other contaminants
- Plus, the bright future of CAR T-cell therapy
Download the Article
Share a little information with us to access the entire article now.
View ArticleContent you'll also find interesting
Recommended Features
Droplet Digital™ PCR (ddPCR™) Is Well Suited for Quantifying Transgene Copy Number
Discover why CAR T-cell therapy is so exciting, common hurdles in development and manufacturing, and how ddPCR technology is a solution for these issues.
Transitioning Your Assay from Quantitative PCR to Droplet Digital™ PCR
Get guidance on how to transition from qPCR to ddPCR technology and the differences to consider between the two methods based on AAV titering assay study.
-
Improving Quality Control in CAR T Cell Manufacturing with Droplet Digital™ PCR
Discover how Droplet Digital PCR provides a robust and sensitive method for monitoring and validating CAR T cell therapies during manufacturing in this article.
